108 search results for: symposium
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.
Head-to-Head Trials of Biologics in CRSwNP
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
Join Professors Matthias Augustin and Sarina Elmariah for an engaging ADVENT symposium as they explore the pivotal role of type 2 inflammation in prurigo nodularis and chronic itch.
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.
ADVENT at NAPNAP 2025
Join experts Jonathan Spergel, MD, PhD, Wanda Phipatanakul, MD, MS, and Jerry Ellen Schonfeld, CPNP, at an educational symposium as they investigate the role of type 2 inflammation in pediatric diseases. The speakers will also discuss the difficulties in diagnosis and burdens patients and their families face.
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.
